SLN
Silence Therapeutics Plc - ADR

395
Mkt Cap
$341.5M
Volume
55,311.00
52W High
$18.29
52W Low
$1.97
PE Ratio
-4.37
SLN Fundamentals
Price
$7.31
Prev Close
$7.23
Open
$7.24
50D MA
$5.60
Beta
0.65
Avg. Volume
63,629.29
EPS (Annual)
-$0.9801
P/B
3.67
Rev/Employee
$373,070.71
Loading...
Loading...
News
all
press releases
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO...
Business Wire·8d ago
News Placeholder
More News
News Placeholder
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Zacks·4mo ago
News Placeholder
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Zacks·5mo ago
News Placeholder
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Zacks·5mo ago
News Placeholder
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release...
Business Wire·9mo ago
News Placeholder
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics plc (Silence or the Company) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the...
Business Wire·11mo ago
News Placeholder
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical stage biotechnology company committed to transforming peoples lives by silencing diseases through precision...
Business Wire·11mo ago
News Placeholder
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. read more...
Benzinga·1y ago
News Placeholder
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical stage biotechnology company committed to transforming peoples lives by silencing diseases through precision...
Business Wire·1y ago
News Placeholder
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
read more...
Benzinga·1y ago

Latest SLN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.